Journal of Advances in Biology & Biotechnology, 2394-1081,Vol.: 16, Issue.: 3
Treat Oculocutaneous Albinism with Gene Therapy
Martin L. Nelwan1* 1Department of Animal Science – Other, Nelwan Institution for Human Resource Development Jl. A. Yani No. 24, Palu, Indonesia.
Martin L. Nelwan1*
1Department of Animal Science – Other, Nelwan Institution for Human Resource Development Jl. A. Yani No. 24, Palu, Indonesia.
(1) Andrzej Kowalski, Department of Biochemistry and Genetics, Institute of Biology, Jan Kochanowski University, Kielce, Poland.
(1) Adam Reich, University of Rzeszow, Poland.
(2) Asaad Ahmed Ghanem, Mansoura University, Egypt.
(3) Silvana Guerriero, University of Bari, Italy.
Complete Peer review History: http://www.sciencedomain.org/review-history/22563
Oculocutaneous albinism (OCA) is a group of hereditary recessive disorder recognized as a loss of pigmentation. OCA can derive from mutations in different genes that produce melanin. These mutations cause disturbances to get a standard melanin synthesis. There are 7 types of oculocutaneous albinism. These include OCA1, OCA2, OCA3, OCA4, OCA5, OCA6, and OCA7. To help OCA patients, it may include management of such as hats with brims and sunscreens. An effective therapy is unavailable for albinism at present. However, to fight OCA in the future, gene therapy can be used. Gene therapy can include use of such as retrovirus vectors, adenovirus vectors, and CRISPR/Cas9 system. Research results in animal models have shown remarkable advances. It means that the gene therapy will be helpful to treat people with albinism.
Albinism; albino; oculocutaneous albinism; gene therapy.
Full Article - PDF Page 1-12
DOI : 10.9734/JABB/2017/38504Review History Comments